James Brumley

James Brumley

James Brumley is a reformed stock broker and former Director of Research for an options-focused newsletter. He’s now primarily a freelance writer, tapping more than a decade’s worth of broad experience to help investors get more out of the market.

With a background in technical analysis as well as fundamental analysis, James writes with a multifaceted philosophy that combines the importance of company performance with the power of stock-trade timing. His commentary is as apt to focus on a chart as it is earnings, as he believes this dual approach is the only way an investor has a shot at consistently beating the market.

James’ work has appeared at several websites, including Street Authority, Motley Fool, Kapitall and Investopedia. When not writing as a journalist, James works on his book explaining his multipronged approach to investing.

Recent Articles

Why Mentor Graphics Corp. (MENT), Sprint Corp (S) and Chipotle Mexican Grill, Inc. (CMG) Are 3 of Today’s Worst Stocks

Mentor Graphics (MENT), Sprint (S) and Chipotle Mexican Grill (CMG) just couldn't get aboard Friday's bullish train for the market.

Tesla Motors Inc: Like It or Not, Tesla Stock IS Losing Steam. Buyers Beware.

Tesla stock may be a market favorite, but a deeper look at the dynamics says TSLA is more out of favor than in favor right now.

Expect Solid Consumer Spending for Holiday 2015

Despite what consumers say (and what they seem to think), consumer spending in November and December should grow measurably.

Why Sunedison Inc (SUNE), Aetna Inc. (AET) and Freeport-McMoRan Inc (FCX) Are 3 of Today’s Worst Stocks

Sunedison (SUNE), Aetna (AET) and Freeport-McMoRan (FCX) were all just victims of circumstances on Thursday, but victims nonetheless.

Pfizer Stock Down, But Hardly Out, On Threats to Tax Inversion Law

Pfizer stock took a hit on concerns that it's union with Allergan could be upended by new tax rules in the meantime, but the odds still favor PFE.